» Articles » PMID: 15184383

Tec Kinases Mediate Sustained Calcium Influx Via Site-specific Tyrosine Phosphorylation of the Phospholipase Cgamma Src Homology 2-Src Homology 3 Linker

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2004 Jun 9
PMID 15184383
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Tyrosine phosphorylation of phospholipase Cgamma2 (PLCgamma2) is a crucial activation switch that initiates and maintains intracellular calcium mobilization in response to B cell antigen receptor (BCR) engagement. Although members from three distinct families of non-receptor tyrosine kinases can phosphorylate PLCgamma in vitro, the specific kinase(s) controlling BCR-dependent PLCgamma activation in vivo remains unknown. Bruton's tyrosine kinase (Btk)-deficient human B cells exhibit diminished inositol 1,4,5-trisphosphate production and calcium signaling despite a normal inducible level of total PLCgamma2 tyrosine phosphorylation. This suggested that Btk might modify a critical subset of residues essential for PLCgamma2 activity. To evaluate this hypothesis, we generated site-specific phosphotyrosine antibodies recognizing four putative regulatory residues within PLCgamma2. Whereas all four sites were rapidly modified in response to BCR engagement in normal B cells, Btk-deficient B cells exhibited a marked reduction in phosphorylation of the Src homology 2 (SH2)-SH3 linker region sites, Tyr(753) and Tyr(759). Phosphorylation of both sites was restored by expression of Tec, but not Syk, family kinases. In contrast, phosphorylation of the PLCgamma2 carboxyl-terminal sites, Tyr(1197) and Tyr(1217), was unaffected by the absence of functional Btk. Together, these data support a model whereby Btk/Tec kinases control sustained calcium signaling via site-specific phosphorylation of key residues within the PLCgamma2 SH2-SH3 linker.

Citing Articles

In BTK, phosphorylated Y223 in the SH3 domain mirrors catalytic activity, but does not influence biological function.

Estupinan H, Bouderlique T, He C, Berglof A, Cappelleri A, Frengen N Blood Adv. 2024; 8(8):1981-1990.

PMID: 38507738 PMC: 11024922. DOI: 10.1182/bloodadvances.2024012706.


Research-based flow cytometry assays for pathogenic assessment in the human B-cell biology of gene variants revealed in the diagnosis of inborn errors of immunity: a Bruton's tyrosine kinase case-study.

Del Pino-Molina L, Bravo Gallego L, Soto Serrano Y, Reche Yebra K, Marty Lobo J, Gonzalez Martinez B Front Immunol. 2023; 14:1095123.

PMID: 37197664 PMC: 10183671. DOI: 10.3389/fimmu.2023.1095123.


Selective Inhibition of Bruton's Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors.

Sousa B, de Almeida C, Barahona A, Lopes R, Martins-Logrado A, Cavaco M ACS Pharmacol Transl Sci. 2022; 5(11):1156-1168.

PMID: 36407952 PMC: 9667546. DOI: 10.1021/acsptsci.2c00163.


Microglia: The Missing Link to Decipher and Therapeutically Control MS Progression?.

Geladaris A, Hausler D, Weber M Int J Mol Sci. 2021; 22(7).

PMID: 33801644 PMC: 8038003. DOI: 10.3390/ijms22073461.


Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP.

Ou Y, Tang Z, Novotny W, Tawashi M, Li T, Coleman H Br J Clin Pharmacol. 2020; 87(7):2926-2936.

PMID: 33336408 PMC: 8359458. DOI: 10.1111/bcp.14707.